President Biden said all U.S. adults should be eligible for COVID-19 vaccination by April 19. That accelerates the original timeline by nearly two weeks, from the previous date of May 1. (The Wall Street Journal)

The Food and Drug Administration extended its review of Pfizer’s experimental skin drug, abrocitinib, by three months. Abrocitinib is part of a class of drugs, JAK inhibitors, that have come under scrutiny for safety concerns. (Reuters)

Novartis expanded its oncology drug pipeline by agreeing to pay up to $1.3 billion for DNA repair-targeted molecules from Artios. The deal comes after Artios agreed to work with Merck on small-molecule drugs that target DNA repair enzymes. (Endpoints News)

More young people are being hospitalized with severe cases of COVID-19, Centers for Disease Control and Prevention director Dr. Rochelle Walensky said. Walensky urged continued precautions as variants spread. (CNBC Weekly)

Merck reached a deal with regulators in Austria after an investigation around “predatory” pricing for a brain cancer drug. Regulators said the company tried to prevent lower-cost generic versions of the drug, Temodal, from reaching the market. (STAT)